Center for Innovative Cancer Treatment, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Department of Orthopedic Surgery, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Int J Clin Oncol. 2023 Sep;28(9):1227-1235. doi: 10.1007/s10147-023-02365-3. Epub 2023 Jun 14.
Real-world data on optimal cancer pain management remain scarce. We describe prescription patterns of analgesics in Japanese cancer patients with bone metastases.
National hospital-based claims data were analyzed. Adults with first diagnosis of cancer during 2015-2019 and first diagnosis of bone metastasis after the initial cancer diagnosis were included. Skeletal-related events (SREs) were identified with disease and receipt codes.
Among the 40,507 eligible patients (age [mean ± SD], 69.7 ± 11.7 years), lung (25.3%), prostate (15.6%), breast (10.9%), and colorectal (10.7%) cancers were common primary tumors. Time (mean ± SD) between primary cancer diagnosis and bone metastases was 306.9 ± 490.4 days; median survival time from bone metastases was 483.0 days. Most patients used acetaminophen (62.7%, 117.5 days/year) and nonsteroidal anti-inflammatory drugs (NSAIDs; 75.3%, 170.0 days/year). Commonly used opioids included oxycodone (39.4%; 479.3 days/year), fentanyl (32.5%; 52.6 days/year), morphine (22.1%; 130.9 days/year), and tramadol (15.3%; 143.0 days/year). Internal medicine, surgery, respiratory, urology, and orthopedics treated 19.4%, 18.5%, 17.6%, 17.3%, and 13.0% of patients, respectively. Prescription patterns varied inter-department. Overall, 44.9% of patients developed SRE (bone pain requiring radiation [39.6%] or orthopedic surgery [2.9%]; hypercalcemia, 4.9%; pathological fracture, 3.3%; spinal cord compression, 0.4%). Analgesics use by patients with SREs was 1.8- to 2.2-fold in the postsymptomatic vs the presymptomatic period. SRE patients had numerically lower survival probabilities than non-SRE patients. Opioid use increased considerably in the month before death.
In Japanese cancer patients with bone metastases, acetaminophen, NSAIDs, and weak or strong opioids were commonly used; their use increased after SREs developed. Opioid use increased closer to death.
关于癌症疼痛管理的真实世界数据仍然很少。我们描述了日本骨转移癌患者的镇痛药处方模式。
分析了全国基于医院的索赔数据。纳入 2015-2019 年首次诊断为癌症且在初始癌症诊断后首次诊断为骨转移的成年患者。通过疾病和收据代码识别骨骼相关事件(SRE)。
在 40507 名合格患者中(年龄[平均值±标准差],69.7±11.7 岁),肺癌(25.3%)、前列腺癌(15.6%)、乳腺癌(10.9%)和结直肠癌(10.7%)是常见的原发性肿瘤。原发性癌症诊断与骨转移之间的时间(平均值±标准差)为 306.9±490.4 天;从骨转移开始的中位生存时间为 483.0 天。大多数患者使用对乙酰氨基酚(62.7%,117.5 天/年)和非甾体抗炎药(NSAIDs;75.3%,170.0 天/年)。常用的阿片类药物包括羟考酮(39.4%,479.3 天/年)、芬太尼(32.5%,52.6 天/年)、吗啡(22.1%,130.9 天/年)和曲马多(15.3%,143.0 天/年)。内科、外科、呼吸科、泌尿科和骨科分别治疗了 19.4%、18.5%、17.6%、17.3%和 13.0%的患者。处方模式因科室而异。总体而言,44.9%的患者发生了 SRE(骨痛需要放疗[39.6%]或骨科手术[2.9%];高钙血症,4.9%;病理性骨折,3.3%;脊髓压迫,0.4%)。与症状前时期相比,SRE 患者在症状出现后使用镇痛药的频率增加了 1.8-2.2 倍。SRE 患者的生存概率明显低于非 SRE 患者。阿片类药物的使用在死亡前 1 个月显著增加。
在日本骨转移癌患者中,对乙酰氨基酚、非甾体抗炎药和弱阿片类或强阿片类药物常用;在发生 SRE 后,这些药物的使用增加。阿片类药物的使用在接近死亡时增加。